Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
362 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02227251 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 244 | Karyopharm Therapeutics IncINDUSTRY | 19 | Jul 2, 2026 | clinicaltrials |
| NCT06558279 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis(ADAPT oculus) | active not recruiting | Phase 3 | 141 | argenxINDUSTRY | 25 | Jul 2, 2026 |
| NCT06578247 | Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML(QuANTUM-WILD) | active not recruiting | Phase 3 | 700 | Daiichi SankyoINDUSTRY | 28 | Jul 2, 2026 | clinicaltrials |
| NCT04248829 | Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) | completed | Phase 3 | 393 | Yuhan CorporationINDUSTRY | 13 | Jun 29, 2026 | clinicaltrials |
| NCT02834884 | SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access(SPECTA) | recruiting | — | 4,975 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 20 | Jun 24, 2026 | clinicaltrials |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | recruiting | — | 9,000 | Genzyme, a Sanofi CompanyINDUSTRY | 44 | Jun 23, 2026 | clinicaltrials |
| NCT05059522 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | active not recruiting | Phase 3 | 77 | PfizerINDUSTRY | 19 | Jun 22, 2026 | clinicaltrials |
| NCT05661578 | A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors(SKYSCRAPER-11) | completed | Phase 2 | 64 | Hoffmann-La RocheINDUSTRY | 9 | Jun 18, 2026 | clinicaltrials |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | active not recruiting | Phase 3 | 4,170 | Hoffmann-La RocheINDUSTRY | 54 | Jun 17, 2026 | clinicaltrials |
| NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | active not recruiting | Phase 3 | 260 | Alexion Pharmaceuticals, Inc.INDUSTRY | 22 | Jun 17, 2026 | clinicaltrials |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC(KANGUROO) | recruiting | Phase 2 / Phase 3 | 71 | Urovant Sciences GmbHINDUSTRY | 16 | Jun 15, 2026 | clinicaltrials |
| NCT04960709 | Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin(VOLGA) | active not recruiting | Phase 3 | 712 | AstraZenecaINDUSTRY | 25 | Jun 4, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
| NCT02075840 | A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants(ALEX) | completed | Phase 3 | 303 | Hoffmann-La RocheINDUSTRY | 29 | May 29, 2026 | clinicaltrials |
| NCT04529122 | A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test | completed | — | 7,864 | Hoffmann-La RocheINDUSTRY | 32 | May 27, 2026 | clinicaltrials |
| NCT06225596 | Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | active not recruiting | Phase 2 | 375 | BicycleTx LimitedINDUSTRY | 21 | May 27, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT00062400 | Assessing Women's Attitudes About the Risk of Infertility Related to Adjuvant Therapy for Early Breast Cancer | completed | N/A | 385 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 15 | May 12, 2026 | clinicaltrials |
| NCT01101425 | Male Breast Cancer: Understanding the Biology for Improved Patient Care | active not recruiting | — | 200 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 16 | May 12, 2026 | clinicaltrials |
| NCT05243550 | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ENVISION) | active not recruiting | Phase 3 | 240 | UroGen Pharma Ltd.INDUSTRY | 10 | May 11, 2026 | clinicaltrials |
| NCT06697301 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | recruiting | Phase 2 / Phase 3 | 740 | Eikon TherapeuticsINDUSTRY | 24 | May 8, 2026 | clinicaltrials |
| NCT06311721 | A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 315 | AmgenINDUSTRY | 23 | May 6, 2026 | clinicaltrials |
| NCT05429268 | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)(firmMIND) | active not recruiting | Phase 3 | 82 | Incyte CorporationINDUSTRY | 14 | May 5, 2026 | clinicaltrials |
| NCT03563716 | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 135 | Genentech, Inc.INDUSTRY | 6 | May 4, 2026 | clinicaltrials |
| NCT05156125 | VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis | terminated | Phase 2 | 213 | Oppilan Pharma LtdINDUSTRY | 14 | Apr 30, 2026 | clinicaltrials |
| NCT05644561 | Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis | active not recruiting | Phase 3 | 12 | Alexion Pharmaceuticals, Inc.INDUSTRY | 5 | Apr 17, 2026 | clinicaltrials |
| NCT06096220 | Usage of 5-fluorouracil and Carnoy's Solution in Surgical Treatment of Odontogenic Keratocysts | enrolling by invitation | Phase 4 | 50 | University of BelgradeOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06064877 | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma(FIERCE-HN) | recruiting | Phase 3 | 410 | AVEO Pharmaceuticals, Inc.INDUSTRY | 18 | Apr 9, 2026 | clinicaltrials |
| NCT06508658 | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(EPCORE DLBCL-4) | active not recruiting | Phase 3 | 379 | GenmabINDUSTRY | 28 | Apr 8, 2026 | clinicaltrials |
| NCT04516447 | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer(MUIR) | recruiting | Phase 1 | 172 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 7 | Apr 7, 2026 | clinicaltrials |
| NCT04256421 | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer(SKYSCRAPER-02) | completed | Phase 3 | 490 | Hoffmann-La RocheINDUSTRY | 23 | Apr 3, 2026 | clinicaltrials |
| NCT03315364 | Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy(OPTIMAL) | active not recruiting | Phase 2 / Phase 3 | 549 | Daehwa Pharmaceutical Co., Ltd.INDUSTRY | 5 | Apr 1, 2026 | clinicaltrials |
| NCT04824092 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients(frontMIND) | active not recruiting | Phase 3 | 899 | Incyte CorporationINDUSTRY | 29 | Apr 1, 2026 | clinicaltrials |
| NCT06430866 | Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)(Eucalyptus) | active not recruiting | Phase 3 | 163 | AmgenINDUSTRY | 18 | Apr 1, 2026 | clinicaltrials |
| NCT05907122 | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma | completed | Phase 3 | 256 | AmgenINDUSTRY | 22 | Mar 27, 2026 | clinicaltrials |
| NCT06093672 | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera(GIV-IN-PV) | recruiting | Phase 3 | 220 | ItalfarmacoINDUSTRY | 16 | Mar 25, 2026 | clinicaltrials |
| NCT04472598 | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis(TRANSFORM-1) | completed | Phase 3 | 252 | AbbVieINDUSTRY | 25 | Mar 23, 2026 | clinicaltrials |
| NCT02973789 | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | completed | Phase 3 | 291 | NovoCure GmbHINDUSTRY | 18 | Mar 18, 2026 | clinicaltrials |
| NCT04777851 | Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7(REPLACE) | terminated | Phase 3 | 45 | Translational Research in OncologyOTHER | 13 | Mar 9, 2026 | clinicaltrials |
| NCT07391813 | SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer(SNB-101-101) | recruiting | Phase 1 / Phase 2 | 55 | SN BioScienceINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07414433 | Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma(BLOOD-TACE-M) | not yet recruiting | — | 60 | University of BelgradeOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07250750 | A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis(Synergy-MG) | recruiting | Phase 1 / Phase 2 | 96 | ImmunAbs Inc.INDUSTRY | 6 | Feb 11, 2026 | clinicaltrials |
| NCT02308085 | Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer(POSITIVE) | active not recruiting | N/A | 518 | ETOP IBCSG Partners FoundationNETWORK | 22 | Feb 9, 2026 | clinicaltrials |
| NCT07378709 | Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma(BLOOD-TACE-P) | recruiting | — | 15 | University of BelgradeOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05419375 | Screening Study for Participants With Malignant Tumors | completed | Phase 2 | 470 | Hoffmann-La RocheINDUSTRY | 26 | Feb 3, 2026 | clinicaltrials |
| NCT04294810 | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer(SKYSCRAPER-01) | completed | Phase 3 | 620 | Hoffmann-La RocheINDUSTRY | 23 | Jan 30, 2026 | clinicaltrials |
| NCT02003924 | Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer(PROSPER) | completed | Phase 3 | 1,401 | PfizerINDUSTRY | 32 | Jan 27, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials